WHO ICTRP trial
Efficacy and Safety of T Cell Receptor Modified T (TCR-T) Cells in Advanced…
ChiCTR2200057171 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2200057171 |
|---|---|
| Public title | Efficacy and Safety of T Cell Receptor Modified T (TCR-T) Cells in Advanced Pancreatic Cancer, Lung Cancer and Colorectal Cancer Therapy |
| Scientific title | Efficacy and Safety of T Cell Receptor Modified T (TCR-T) Cells in Advanced Pancreatic Cancer, Lung Cancer and Colorectal Cancer Therapy |
| Primary sponsor | Intervention and Cell Therapy Center, Peking University Shenzhen Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Advanced pancreatic cancer, lung cancer and colorectal cancer |
| Interventions | experimental group:TCR-T treatment |
| Registration date | Mar 2, 2022 |
| Target size | experimental group:10 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: